



Ms J Gambell
CANCER RESEARCH UK & UNIV. COLL. LONDON CANCER TRIALS CENTRE
HAEMATOLOGY TRIALS GROUP
90 TOTTENHAM COURT ROAD
LONDON
W1T 4TJ
UNITED KINGDOM

23/02/2010

Dear Ms J Gambell

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference:	20363/0273/001-0002
Eudract Number:	2009-012717-22
Product:	rituximab
Protocol number:	UCL/08/0167
Substantial Amendment Code Number:	Amendment 1/PIS v2.0 & MREC Approval/20jan10

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 22/01/2010.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit
MHRA**

